IRVINE, Calif., March 28, 2024 Reneo Pharmaceuticals, Inc. , a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic.
The STRIDE study did not meet its primary or secondary efficacy endpoint The company to suspend mavodelpar development and implement a workforce reduction IRVINE, Calif., Dec. 14, 2023 Reneo.
Reneo Pharmaceuticals Announces Results from Pivotal STRIDE globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Topline data results from the pivotal STRIDE study are expected in December 2023IRVINE, Calif., Nov. 13, 2023 Reneo Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the.